The results of our analysis suggest that INH prophylaxis reduces the risk of TB by 59% among children ≤ 15 years of age, excluding a subset of young children on whom INH was initiated at four ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.

Evaluation of the Xpert MTB/RIF Test for the Diagnosis of Childhood Pulmonary Tuberculosis in Uganda A Cross-sectional Diagnostic Study ...

The attack data in RAPIDe-3 have continued to accrue following the achievement of target enrollment in the study; we now estimate that our RAPIDe-3 topline data announcement will be in the fourth ...

Received FDA approval of EKTERLY® (sebetralstat)-the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway - - Six additional global regulatory submissions under ...

Hereditary angioedema (HAE) is a genetic disorder that causes sudden episodes of swelling, often accompanied by abdominal pain. Affecting roughly 1 in 50 000 people, HAE typically appears in childhood ...

With positive data in both Phase 2 prophylaxis and on-demand studies in HAE ... our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH ...

Objective: To study the efficacy of isoniazid prophylaxis (INHP) in patients with systemic lupus erythematosus (SLE) receiving long term glucocorticosteroid treatment. Patients and methods: Treatment ...

By targeting a previously unexploited metabolic pathway essential for bacterial survival, the drug candidate may offer the potential to develop safer, shorter and more effective treatment regimens ...

We have previously demonstrated that the introduction of rifampicin and isoniazid prophylaxis locally significantly reduced the incidence of paediatric tuberculosis (TB), 8 and that the reduction in ...

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...

The FDA has approved Andembry for prophylactic use to prevent attacks of HAE in adult and pediatric patients aged 12 years and older.